Image for Rapid ID+AST pilot study highlighted at ECCMID 2020

Rapid ID+AST pilot study highlighted at ECCMID 2020

The pilot study, led by Gradientech, combined rapid ID+AST technologies – T2Bacteria (ID) and QuickMIC (AST) and compared the time-to-result to a workflow using standard laboratory methods.

The rapid diagnostic workflow provided same-shift results (9.5h) that were significantly faster than the standard workflow (53h). Interestingly, in 68% of the cases, rapid ID+AST results were available before blood cultures had turned positive.

This study highlights the potential of combining rapid ID+AST diagnostic technologies for reducing the time to targeted treatment initiation for sepsis patients.

Link to ECCMID 2020 abstract

For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80

Gradientech is an ISO13485 certified company since 2017


Gradientech AB
Uppsala Science Park
SE-751 83 Uppsala

About Gradientech

Gradientech develops, manufactures and sells innovative microfluidic products for high-quality analysis of the behavior of cells and organisms in response to gradients of biomolecules. Our aim is to pioneer life science and healthcare.

Copyright © 2023 Gradientech. All rights reserved. Gradientech, QuickMIC and CellDirector are registered trademarks or trademarks of Gradientech AB.

Next-generation antimicrobial susceptibility testing

Take a look at our E-book